Detalhe da pesquisa
1.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 385(12): 1091-1103, 2021 09 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34161051
2.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(6): 597-610, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37269841
3.
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Breast Cancer Res
; 16(4): 405, 2014 Jul 24.
Artigo
Inglês
| MEDLINE | ID: mdl-25056500
4.
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Breast Cancer Res Treat
; 143(3): 493-505, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24402830
5.
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Eur Urol
; 85(4): 382-391, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38185538
6.
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Breast Cancer Res Treat
; 137(2): 457-64, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23224144
7.
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Oncology
; 79(1-2): 129-35, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-21088439
8.
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Lancet Oncol
; 10(6): 581-8, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19394894
9.
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Clin Cancer Res
; 25(5): 1472-1478, 2019 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30563934
10.
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Int J Radiat Oncol Biol Phys
; 69(4): 1117-23, 2007 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17689883
11.
Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
Int J Radiat Oncol Biol Phys
; 67(1): 39-47, 2007 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17084551
12.
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
Int J Radiat Oncol Biol Phys
; 69(3): 646-55, 2007 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17531401
13.
Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14.
Int J Radiat Oncol Biol Phys
; 66(1): 229-33, 2006 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16814950
14.
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
Int J Radiat Oncol Biol Phys
; 66(1): 25-30, 2006 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16814949
15.
A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.
Int J Radiat Oncol Biol Phys
; 64(3): 804-9, 2006 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16289906
16.
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
Int J Radiat Oncol Biol Phys
; 64(4): 1162-7, 2006 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16427211
17.
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
Int J Radiat Oncol Biol Phys
; 66(3): 647-53, 2006 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17011443
18.
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
Int J Radiat Oncol Biol Phys
; 65(4): 975-81, 2006 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16750319
19.
Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
Int J Radiat Oncol Biol Phys
; 62(4): 956-64, 2005 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15989995
20.
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
JAMA
; 294(10): 1233-9, 2005 Sep 14.
Artigo
Inglês
| MEDLINE | ID: mdl-16160131